Rhodococcus hoagii: Difference between revisions
From IDWiki
Rhodococcus hoagii
m (Text replacement - "Rhodococcus equi" to "Rhodococcus hoagii") |
(→: added a bit more clues for identification) |
||
Line 3: | Line 3: | ||
*Facultative intracellular, non-spore-forming, [[Stain::Gram-positive]], weakly acid-fast [[Shape::coccobacillus]] |
*Facultative intracellular, non-spore-forming, [[Stain::Gram-positive]], weakly acid-fast [[Shape::coccobacillus]] |
||
**More coccoid when grown on solid media, and more bacillary with varying lengths (often beaded) when grown in liquid media |
|||
*Within the family [[Nocardiaceae]] and order [[Actinomycetes]] |
*Within the family [[Nocardiaceae]] and order [[Actinomycetes]] |
||
*Obligate aerobic and facultatively intracellular |
*Obligate aerobic and facultatively intracellular |
||
Line 36: | Line 37: | ||
**Gastrointestional inoculation followed by lymphatic dissemination, causing peritonitis, pelvic masses, and mesenteric adenitis |
**Gastrointestional inoculation followed by lymphatic dissemination, causing peritonitis, pelvic masses, and mesenteric adenitis |
||
**Others include otitis media with mastoiditis, colonic polyp infection, and osteomyelitis |
**Others include otitis media with mastoiditis, colonic polyp infection, and osteomyelitis |
||
== Diagnosis == |
|||
* May be misidentified as [[Corynebacterium]] in blood culture or [[Kocuria]] on Vitek |
|||
==Management== |
==Management== |
Latest revision as of 16:49, 31 August 2022
Background
Microbiology
- Facultative intracellular, non-spore-forming, Gram-positive, weakly acid-fast coccobacillus
- More coccoid when grown on solid media, and more bacillary with varying lengths (often beaded) when grown in liquid media
- Within the family Nocardiaceae and order Actinomycetes
- Obligate aerobic and facultatively intracellular
- Found in dry and dusty soil
- Makes red pigment, hence the name
Epidemiology
- Infects domesticated animals: Horses (and in foals it causes pneumonia), Goats, Pigs, Sheep, and Cattle
- Most commonly infects people with cell-mediated immunodeficiency, particularly HIV, with or without a notable infectious exposure
Risk Factors
- HIV accounts for 65% of cases
- Solid organ and hematopoietic stem cell transplantation
- Diabetes
- Alcohol abuse
- Chronic renal failure
- Leukemia, lymphoma, lung cancer
- Sarcoidosis
- Preterm infants
Clinical Manifestations
- Necrotizing pneumonia is usual presentation, as well as nodules, cavitation, pleural effusion, and lung abscess
- Typically subacute onset with fever, cough, and fatigue, as well as pleuritic chest pain
- Specifically in immunocompromised patients, it can cause a cavitary lung disease and is on the differential with mycobacteria and nocardiosis
- Extrapulmonary disease can occur with or without pulmonary involvement
- In conjunction with other infections, can have abscesses in liver, spleen, thyroid, kidney, psoas, bone, prostate, intraabdominal cavity, and paraspinous tissue
- Extrapulmonary disease without pulmonary involvement has three main presentations:
- Localized infection following traumatic inoculation, causing wound infection, traumatic septic arthritis, or endophthalmitis
- Isolated bacteremia with fever, typically recently after chemotherapy causing neutropenia
- Gastrointestional inoculation followed by lymphatic dissemination, causing peritonitis, pelvic masses, and mesenteric adenitis
- Others include otitis media with mastoiditis, colonic polyp infection, and osteomyelitis
Diagnosis
- May be misidentified as Corynebacterium in blood culture or Kocuria on Vitek
Management
- Recommend using at least two agents given increasing rates of resistance
- First-line: combination of macrolide or fluoroquinolone plus rifampin
- First-line: combination of macrolide or fluoroquinolone plus two of: vancomycin, imipenem, linezolid, or an aminoglycoside
- Doses are:
- Azithromycin 500 mg PO/IV once followed by 250 mg PO/IV daily
- Fluoroquinolones: moxifloxacin 400 mg PO daily (preferred), levofloxacin 500 mg PO daily, or ciprofloxacin 750 mg PO BID
- Rifampin 600 mg PO once daily
- Increasing resistance to doxycycline, rifampin, and TMP-SMX
- Treatment usually 6 months or longer